The evolving clinical testing landscape of genomic aberrations in solid tumors and hematological malignancies – Insights from evidence-based reviews for B-ALL and breast, brain, and renal cell neoplasia-Reference-Cited by-同舟云学术

The evolving clinical testing landscape of genomic aberrations in solid tumors and hematological malignancies – Insights from evidence-based reviews for B-ALL and breast, brain, and renal cell neoplasia

Published:2020-06 Issue: Volume:244 Page:60-61
ISSN:2210-7762
Container-title:Cancer Genetics
language:en
Short-container-title:Cancer Genetics

Author:

Miron Patricia M.,Fang Min

Publisher

Elsevier BV

Subject

Cancer Research,Genetics,Molecular Biology

Reference12 articles.

1. Assessing copy number aberrations and copy-neutral loss-of-heterozygosity across the genome as best practice: an evidence-based review from the Cancer Genomics Consortium (CGC) working group for chronic lymphocytic leukemia;Chun;Cancer Genet,2018

2. Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative neoplasms

3. Assessing genome-wide copy number aberrations and copy-neutral loss-of-heterozygosity as best practice: an evidence-based review from the Cancer Genomics Consortium working group for plasma cell disorders;Pugh;Cancer Genet,2018

4. Assessing copy number abnormalities and copy-neutral loss-of-heterozygosity across the genome as best practice in diagnostic evaluation of acute myeloid leukemia: An evidence-based review from the cancer genomics consortium (CGC) myeloid neoplasms working group

5. NCCN Clinical Practice Guidelines in Oncology for Myelodysplastic Syndromes. Version 1. 2020 August 27, 2019. NCCN.org.